Transdermal estradiol in castrate and chemotherapy resistant prostate cancer.
Fiche publication
Date publication
avril 2012
Journal
Medical science monitor : international medical journal of experimental and clinical research
Auteurs
Membres identifiés du Cancéropôle Est :
Dr METZGER Daniel
Tous les auteurs :
Stein M, Goodin S, Doyle-Lindrud S, Silberberg J, Kane M, Metzger D, Eddy S, Shih W, DiPaola RS
Lien Pubmed
Résumé
Given prior studies demonstrating the marked clinical activity of oral estrogens in prostate cancer, more recent data demonstrating the safety of transdermal estradiol, and the renewed interest in targeting testosterone metabolism and androgen receptor pathways, we report the results of a trial of transdermal estradiol in advanced heavily pre-treated castrate and chemotherapy refractory patients.
Mots clés
Administration, Cutaneous, Aged, Aged, 80 and over, Castration, Demography, Drug Resistance, Neoplasm, Estradiol, administration & dosage, Humans, Male, Middle Aged, Prostatic Neoplasms, blood, Testosterone, blood
Référence
Med. Sci. Monit.. 2012 Apr;18(4):CR260-4